Steven Howard

Company: Astex Therapeutics Ltd

Job title: Director

Seminars:

Demonstrating Fragment-Based Drug Discovery of ASTX029, a Dual Mechanism ERK1/2 Inhibitor 2:45 pm

Describing the fragment-based drug discovery of ASTX029, a dual-mechanism ERK1/2 (ERK) inhibitor that suppresses both the catalytic activity and phosphorylation of ERK Highlighting the opportunity that ASTX029 offers as a potent inhibitor of MAPK-activated tumor growth in preclinical models Showcasing ASTX029, which is currently undergoing clinical development in a Ph1/2 trial in advanced solid tumorsRead more

day: Day 2 Track A PM